Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + vitamin D
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of metformin, a biguanide antihyperglycemic agent, and vitamin D (cholecalciferol). This combination has shown synergistic effects in preclinical studies for colorectal neoplasia prevention and management of type 2 diabetes mellitus complications. The synergistic mechanisms involve metformin's action through the AMPK/mTOR pathway and vitamin D's effects via the vitamin D receptor/β-catenin pathway.
02
Targets
mTOR (Mammalian target of rapamycin kinase)AMPK (Adenosine monophosphate–activated protein kinase)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on metformin + vitamin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + vitamin D.